Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Isarna Therapeutics on License Agreement with Santaris Pharma

January 13, 2014

LONDON, 13 January, 2014 — Covington & Burling advised Isarna Therapeutics GmbH on an agreement with Santaris Pharma A/S whereby Isarna gains access to Santaris' Locked Nucleic Acid (LNA) technology to further develop its next generation oligonucleotide product candidates. Under the terms of the agreement, Isarna obtains rights to utilize Santaris Pharma's proprietary LNA Drug Platform to discover, develop and commercialize immunotherapeutics targeted against the cytokine transforming growth factor ß 1, ß 2 and ß 3 (TGF- ß).

Isarna Therapeutics GmbH is a German privately held biotechnology company focused on development of TGF‐β inhibitors for treatment of cancer. Santaris Pharma A/S is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, headquartered in Denmark with operations in the United States.

The Covington team was led by Daniel Pavin and included Gregor Frizzell and associate Zafar Qadir.

Share this article: